Posted by Michael Wonder on 25 May 2023
Celltrion USA announces US FDA approval of Yuflyma (adalimumab-aaty), a high concentration and citrate free formulation of Humira (adalimumab) biosimilar
24 May 2023 - Yuflyma is FDA approved to treat eight conditions including Crohn’s disease and ulcerative colitis.
Celltrion USA today announced that the US FDA has approved Yuflyma (adalimumab-aaty), a high concentration (100 mg/mL) and citrate free formulation of Humira (adalimumab) biosimilar.
